1 Brusnakov M.Yu., Golovchenko O.V., Potikha L.M., and Brovarets V.S. (2023) Condensed azole-based organophosphorus heterocycles. Chem. Het. Comp., 59 (4-5) 213-236.
2 Los O.V., Sinenko V.O., Kobzar O., Zhirnov V., Vovk A.I., and Brovarets V.S. (2023) Synthesis and in vitro anticancer potential of new thiazole-containing derivatives of rhodanine. Chem. Het. Comp., 59 (6-7) 489-493.
3 Guzyr O.I., Potikha L.M., Shishkina S.V., Fetyukhin V.N., and Shermolovich Y.G. (2023) The nitration and bromination of 2-(pentafluorosulfanyl)-1,3-benzothiazole and 2-(trifluoromethyl)-1,3-benzothiazole Chem. Het. Comp., 59 (4-5) 304-308.
4 Wood J.M., Furkert D.P., and Brimble M.A. (2019) 2-Formylpyrrole natural products: origin, structural diversity, bioactivity and synthesis. Nat. Prod. Rep., 36 (2) 289-306.
5 Seipp K., Geske L., and Opatz T. (2021) Marine pyrrole alkaloids. Mar. Drugs, 19 (9) 514.
6 Ferrari S. M., Centanni M., Virili C., Miccoli M., Ferrari P., Ruffilli I., Ragusa F., Antonelli A., and Fallahi P. (2019) Sunitinib in the treatment of thyroid cancer. Curr. Med. Chem., 26 (6) 963-972.
7 Anderson T.J., Grégoire J., Pearson G.J., Barry A.R. and oth. (2016) Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol., 32 (11) 1263-1282.
8 Lee J., and Cordrey M.D. (1976) Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies. J. Am. Geriatr. Soc., 24 (10) 440-446.
9 Deutschenbaur L., Beck J., Kiyhankhadiv A., Mühlhauser M., Borgwardt S., Walter M., Hasler G., Sollberger D., and Lang U.E. (2016) Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 64 (32) 325-333.
10 Parikh S. A., Kantarjian H., Schimmer A., Walsh W., Asatiani E., El-Shami K., Winton E., and Verstovsek S. (2010) Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 10 (4) 285-289.
11 Fukuda T., Ishibashi F., and Iwao M. (2020) Lamellarin alkaloids: Isolation, synthesis, and biological activity. Alkaloids Chem. Biol., 83 1-112.
12 Iqbal S., Rasheed H., Awan R. J., Awan R. J., Mukhtar A., and Moloney M. G. (2020) Recent advances in the synthesis of pyrroles. Curr. Org. Chem., 24 1196-1229.
13 Herath A.K., and Lovely C.J. (2021) Pyrrole carboxamide introduction in the total synthesis of pyrrole–imidazole alkaloids. Org. Biomol. Chem., 19 (12) 2603-2621.
14 Philkhana S.C., Badmus F.O., Dos Reis I.C., and Kartika R. (2021) Recent Advancements in Pyrrole Synthesis. Synthesis, 53 (09) 1531-1555.
15 Petri G., Spanò V., Spatola R., Holl R., Raimondi M. V., Barraja P., and Montalbano A. (2020) Bioactive pyrrole-based compounds with target selectivity. Eur. J. Med. Chem., 208 112783.
16 Mateev E., Georgieva M., and Zlatkov A. (2022) Pyrrole as an important scaffold of anticancer drugs: recent advances. J. Pharm. Sci., 25 24-40.
17 Basha N. J., Basavarajaiah S. M., and Shyamsunder K. (2022) Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Mol. Divers., 26 2915-2937.
18 Bhardwaj V., Gumber D., Abbot V., Dhiman S., and Sharma P. (2015) Pyrrole: a resourceful small molecule in key medicinal hetero-aromatics. RSC Advances, 5 15233-15266.
19 Kumar A., and Tadigoppula N. (2017) Metal-free synthesis of polysubstituted pyrroles using surfactants in aqueous medium. Green Chem., 19 5385-5389.
20 Ponduri R., Kumar P., and Vadali L .R. (2018) PEG-400 promoted a simple, efficient, and recyclable catalyst for the one-pot eco-friendly synthesis of functionalized isoxazole substituted pyrroles in aqueous medium. Synth. Commun., 48 (24) 3113-3122.
21 Fox R. J., Cuniere N. L., Bakrania L., Wei C., Strotman N.A., Hay M., Fanfair D., Regens C., Beutner G.L., Lawler M., Lobben P., Soumeillant M.S., Cohen B., Zhu K., Skliar D., Rosner T., Markwalter C.E., Hsiao Y., Tran K., and Eastgate M.D. (2019) C-H Arylation in the formation of a complex pyrrolopyridine, the commercial synthesis of the potent JAK2 inhibitor, BMS-911543. J. Org. Chem., 84 (8) 4661-4669.
22 Han Y., Sun Y., Sun J., and Yan C.-G. (2012) Efficient synthesis of pentasubstituted pyrroles via one-pot reactions of arylamines, acetylenedicarboxylates, and 3-phenacylideneoxindoles. Tetrahedron, 68 8256-8266.
23 dos Santos Fernandes G. F., Moreno-Viguri E., Santivañez-Veliz M., Paucar R., Chin Ch. M., Pérez-Silanes S., and dos Santos J. L. (2017) A comparative study of conventional and microwave-assisted synthesis of quinoxaline 1,4-di-N-oxide N-acylhydrazones derivatives designed as antitubercular drug candidates. J. Het. Chem., 54 (4) 2380-2388.
24 Shirato S., Kagaya F., Suzuki Y., and Joukou S. (1997) Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol., 115 (4) 550-553.
25 Enanga B., Ariyanayagam M.R., Stewart M.L., and Barrett M.P. (2003) Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. Antimicrobial Agents and Chemotherapy, 47 (10) 3368-3370.
26 Wahlig H., Dingeldein E., Mitsuhashi S., and Kawabe H. (1979) Cefazedone: microbiological evaluation in comparison with cephalothin and cefazolin. Arzneimittelforschung, 29 (2a) 369-378.
27 Antosz K., Battle S., Chang J., Scheetz M. H., Al Hasan M., and Bookstaver P. B. (2023) Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation. Pharmacotherapy, 43 (1) 85-95.
28 Matysiak J. (2015) Biological and pharmacological activities of 1,3,4-thiadiazole based compounds. Mini Rev. Med. Chem., 15 (9) 762-775.
29 Haider S., Alam M. S., and Hamid H. (2015) 1, 3, 4-Thiadiazoles: A potent multi targeted pharmacological scaffold. Eur. J. Med. Chem., 92 156-177.
30 Shawali A. S. (2014) 1, 3, 4-Thiadiazoles of pharmacological interest: Recent trends in their synthesis via tandem 1, 3-dipolar cycloaddition. J. Adv. Res., 5 1-17.
31 Serban G., Stanasel O., Serban E., and Bota S. (2018) 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Design, Development and Therapy, 12 1545-1566.
32 Serban G. (2019) Future prospects in the treatment of parasitic diseases: 2-amino-1, 3, 4-thiadiazoles in leishmaniasis. Molecules, 24 (8) 1557.
33 Serban G. (2020) 2-Amino-1, 3, 4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses. Acta Pharm., 70 (3) 259-290.
34 Grozav A.N., Fedoriv M.Z., ChornousV.A., Palamar A.A., BratenkoM.K., and VovkM.V. (2019) Synthesis of thieno[2,3-b]pyrrole-2(4)-carboxylic and 2,4-dicarboxylic acids. Chem. Het. Compd., 55 (4) 435-441.
35 Kemskyi S., Fedoriv M., Palamar A., Grozav A., Chornous V., Kutsyk R., Dorokhov V., and Vovk M. (2023) Synthesis and evaluation of antimicrobial activity of some new 3-(pyrrol-4-yl)acrylamide derivatives. Curr. Chem. Lett., 12 (3) 519-528.
36 Micheli F., Bernardelli A., Bianchi F., Braggio S., Castelletti L., Cavallini P., Cavanni P., Cremonesi S., Dal Cin M., Feriani A., Oliosi B., Semeraro T., Tarsi L., Tomelleri S. Wong A., Visentini F., Zonzini L., and Heidbreder C. (2016) 1, 2, 4-Triazolyl octahydropyrrolo [2,3-b]pyrroles: a new series of potent and selective dopamine D3 receptor antagonists. Bioorg. Med. Chem., 24 (8) 1619-1636.
37 Micheli F., Bacchi A., Braggio S., Castelletti L., Cavallini P., Cavanni P., Cremonesi S., Dal Cin M., Feriani A., Gehanne S., Kajbaf M., Marchió L., Nola S., Oliosi B., Pellacani A., Perdonà E., Sava A., Semeraro T., Tarsi L., Tomelleri S., Wong A., Visentini F., Zonzini L., and Heidbreder C. (2016) 1, 2, 4-Triazolyl 5-azaspiro[2,4]heptanes: lead Identification and early lead optimization of a new series of potent and selective dopamine D3 receptor antagonists. J. Med. Chem., 59 (18) 8459-8576.
38 Khanfar M.A., Reiner D., Hagenow S., and Stark H. (2018) Design, synthesis, and biological evaluation of novel oxadiazole-and thiazole-based histamine H3R ligands. Bioorg. Med. Chem., 26 (14) 4034-4046.
39 Khanfar M. A. (2022) Oxadiazol-based mTOR inhibitors with potent antiproliferative activities: synthetic and computational modeling. Mol. Diversity, 26 (6) 3357-3364.
40 Sayiner H. S., Yilmazer M. I., Abdelsalam A. T., and Ganim M. A. (2022) Synthesis and characterization of new 1, 3, 4-thiadiazole derivatives: study of their antibacterial activity and CT-DNA binding. RSC Adv., 12, 29627-29639.
41 Stojowska-Swędrzyńska K., Łupkowska A., Kuczyńska-Wiśnik D., and Laskowska E. (2021) Antibiotic heteroresistance in Klebsiella pneumoniae. Int. J. Mol. Sci., 23 (1), 449.
42 Firsch M. J., Trucks G. W., and Schlegel H. B. (2016) Gaussian 09, Revision A.02, Wallingford CT.
43 Gázquez J. L., Cedillo A., and Vela A. (2007) Electrodonating and electroaccepting powers. J. Phys. Chem. A, 111 (10) 1966-1970.
44 Domingo, L., Ríos-Gutiérrez, M., and Pérez, P. (2016) Applications of the сonceptual density functional theory indices to organic chemistry reactivity. Molecules, 21(6), 748.
45 El-Sheshtawy H.S., Ibrahim M.M., El-Mehasse, I., and El-Kemar, M. (2015) Orthogonal hydrogen/halogen bonding in 1-(2-methoxyphenyl)-1H-imidazole-2(3H)-thione-I2 adduct: An experimental and theoretical study. Spectrochim. Acta A Mol. Biomol, 143 120-127.
46 Murray J. S., and Politzer P. (2011) The electrostatic potential: an overview. Wiley Interdiscip. Rev. Comput. Mol. Sci., 1 (2) 153-163.
47 Trott O., and Olson A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31 455-461.
48 Kowalska-Krochmal B., and Dudek-Wicher R. (2021). The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens, 10(2), 165.
49 Nazarchuk O. A. (2016) Antiseptics: modern strategy of struggle with causing agents of the іnfection complications. Klin Khir., 9 59-61.
50 Crowley P.D., and Gallagher H.C. (2014) Clotrimazole as a pharmaceutical: past. present and future. J. Appl. Microbiol., 117 (3) 611-617.